公开(公告)号：US20220160769A1

公开(公告)日：2022-05-26

申请号：US17598917

申请日：2020-03-27

申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Yee Sook CHO ,  Han-Seop KIM ,  Jae Yun KIM ,  Binna SEOL

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N15/86 ,  C12N5/0783

摘要： The present invention relates to: a method for producing immunocytes, specifically induced natural killer T (iNKT) cells that are induced by direct reprogramming of isolated somatic cells, and chimeric antigen receptor (CAR)-iNKT cells into which a CAR gene encoding a CAR is introduced; iNKT cells produced by the method; and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNKT cells.
The method according to the present invention can produce, through direct reprogramming, iNKT cells or iNKT cells into which a CAR gene is introduced, from isolated cells so as to simplify the production process and shorten production time, thereby reducing costs, to have excellent NKT cell production efficiency, and to ensure safety according to the production without passing through induced pluripotent stem cells, thereby having an excellent NKT cell production effect distinguished from that of a conventional reprogramming technique. In addition, the iNKT cells or iNKT cells into which a CAR gene is introduced, which are produced by the method, have an excellent cancer cell killing ability, and thus can be effectively used as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.

公开(公告)号：US20220184128A1

公开(公告)日：2022-06-16

申请号：US17598916

申请日：2020-03-27

申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Yee Sook CHO ,  Han-Seop KIM ,  Jae Yun KIM ,  Binna SEOL

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/47 ,  C07K14/435 ,  A61P35/00

摘要： The present invention relates to a method for producing induced natural killer (iNK) cells, into which a chimeric antigen receptor (CAR) gene encoding a CAR is introduced, iNK cells produced by the method, and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, comprising the iNK cells.
The method according to the present invention has the effects of producing the iNK cells, into which a CAR gene is introduced, with high efficiency through direct reprogramming from isolated cells without limiting an initial cell, and directly producing the same without a differentiation process, thereby simplifying the production process and reducing costs and time. The method according to the present invention has the effect of producing excellent NK cells having enhanced safety by directly producing NK cells from human somatic cells that are easy to obtain, without passing through induced pluripotent stem cells produced through conventional reprogramming technology. In addition, the iNK cells, into which a CAR gene is introduced, produced by the method, have an excellent cancer cell killing ability, and thus can be effectively utilized as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.